Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2013-01-01 / Oncoimmunology 2013 Jan;2(1):e22664α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial
/in Dendritic Cells, Glioblastoma, International Publications /von 2012-12-27 / BMC Cancer 2012 Dec;12:623The immunological response and post-treatment survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2012-12-15 / Cancer Immunol. Immunother. 2013 Apr;62(4):761-72Enhanced therapeutic effect of B cell-depleting anti-CD20 antibodies upon combination with in-situ dendritic cell vaccination in advanced lymphoma
/in Dendritic Cells, International Publications, Malignant Lymphoma /von 2012-12-01 / Clin. Exp. Immunol. 2012 Dec;170(3):291-9Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2012-11-01 / Clin. Exp. Immunol. 2012 Nov;170(2):167-77Targeting cancer stem cells via dendritic-cell vaccination
/in Dendritic Cells, International Publications /von 2012-11-01 / Oncoimmunology 2012 Nov;1(8):1401-1403Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy
/in Dendritic Cells, International Publications /von 2012-11-01 / J. Cell. Mol. Med. 2012 Nov;16(11):2827-37Dendritic cell-based tumor vaccinations in epithelial ovarian cancer: a systematic review
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2012-10-01 / Immunotherapy 2012 Oct;4(10):995-1009Dendritic cell-based immunotherapy in mesothelioma
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma /von 2012-10-01 / Immunotherapy 2012 Oct;4(10):1011-22IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de